{
    "clinical_study": {
        "@rank": "92527", 
        "arm_group": [
            {
                "arm_group_label": "patisiran (ALN-TTR02)", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Sterile Normal Saline (0.9% NaCl)", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK)\n      of patisiran (ALN-TTR02) in Japanese subjects"
        }, 
        "brief_title": "A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Transthyretin (TTR)-Mediated Amyloidosis", 
        "condition_browse": {
            "mesh_term": "Amyloidosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy Japanese adult males and females aged 20 to 65 years, inclusive (The subject\n             was born in Japan and has lived outside of Japan for <10 years, and subject's\n             biological parents and grandparents are fully Japanese and were born in Japan);\n\n          -  Subjects who are healthy as determined by clinical assessments;\n\n          -  Females subjects must be of non-childbearing potential;\n\n          -  Males with partners of child-bearing potential, must agree to use appropriate\n             contraception.\n\n        Exclusion Criteria:\n\n          -  Subjects with a history of serious mental illness;\n\n          -  Subjects who have a clinically relevant medical or surgical history;\n\n          -  Subjects with a positive screen for alcohol or drugs of abuse;\n\n          -  Subjects with safety laboratory test results deemed clinically significant;\n\n          -  Subjects with known hepatitis B surface antigen (HBsAg), hepatitis B virus (HBV),\n             hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection;\n\n          -  Subjects who have received an investigational agent within the 3 months prior to\n             study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02053454", 
            "org_study_id": "ALN-TTR02-005"
        }, 
        "intervention": [
            {
                "arm_group_label": "patisiran (ALN-TTR02)", 
                "description": "Ascending doses administered by intravenous (IV) infusion", 
                "intervention_name": "patisiran (ALN-TTR02)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sterile Normal Saline (0.9% NaCl)", 
                "description": "Calculated volume to match active comparator", 
                "intervention_name": "Sterile Normal Saline (0.9% NaCl)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "RNAi therapeutic", 
        "lastchanged_date": "April 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "NW10 7EW"
                }, 
                "name": "Clinical Site"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of ALN-TTR02 in Japanese Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Alnylam Pharmaceuticals", 
            "last_name": "Jared Gollob, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs) and study drug discontinuation", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02053454"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacodynamics (PD) of ALN-TTR02 (serum concentrations of Transthyretin, Vitamin A, and Retinol Binding Protein)", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days"
            }, 
            {
                "measure": "Observed maximum concentration (Cmax) of ALN-TTR02", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days"
            }, 
            {
                "measure": "Time of observed maximum concentration (tmax) of ALN-TTR02", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days"
            }, 
            {
                "measure": "Area under the plasma concentration versus time curve (AUC) of ALN-TTR02", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days"
            }, 
            {
                "measure": "Terminal elimination half-life (t1/2) of ALN-TTR02", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days"
            }, 
            {
                "measure": "Systemic clearance (CL) of ALN-TTR02", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days"
            }, 
            {
                "measure": "Volume of distribution (V) of ALN-TTR02", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days"
            }, 
            {
                "measure": "Renal clearance (CLR) of ALN-TTR02", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days"
            }
        ], 
        "source": "Alnylam Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alnylam Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}